Latest Breaking News On - Jerome jabbour - Page 1 : vimarsana.com

Matinas BioPharma Holdings, Inc (AMEX:MTNB) Q1 2024 Earnings Call Transcript

Matinas BioPharma Holdings, Inc (AMEX:MTNB) Q1 2024 Earnings Call Transcript
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United statesHui liuJerome jabbourKeith kucinskiTerry fergusonAmerican society of geneChief medical officerAmerican societyCell therapyChief technology officerTide united states

Matinas BioPharma Holdings, Inc (AMEX:MTNB) Q4 2023 Earnings Call Transcript

Operator: Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

New jerseyUnited statesJulian harrisonTerri matkovitsTerry fergusonAsia pacificKeith kucinskiJerome jabbourMatinas biopharmaJames fergusonJerry jabbourRobert leboyerTheresa matkovitsJody cainExchange commissionCompassionate expanded use access program

BioNTech and Matinas collaborate on mRNA vaccines

BioNTech and Matinas collaborate on mRNA vaccines
thechemicalengineer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thechemicalengineer.com Daily Mail and Mail on Sunday newspapers.

Matinas biopharmaJerome jabbourUgur sahin

Why Matinas BioPharma Stock Crashed Today

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Matinas BioPharma Holdings (NYSEMKT:MTNB) were crashing 32.7% lower as of 3:01 p.m. EST on Monday. The steep decline came after the company announced disappointing results from a phase 2 clinical study of Lypdiso in reducing triglycerides. So what Matinas had good news and bad news. The good news was that Lypdiso beat Amarin s (NASDAQ:AMRN) Vascepa in increasing eicosapentaenoic acid (EPA) levels in study participants blood. It wasn t even close, with Lypdiso demonstrating a 46% increase in EPA from baseline compared to Vascepa.

Jerome jabbourMatinas biopharma holdingsஜெரோம் ஜபூர்